Ipamorelin Dosage Protocol: Timing, Frequency, and Subcutaneous Injection Technique (2026)

Ipamorelin Dosage: What the Evidence Actually Says

Ipamorelin dosage for subcutaneous injection typically falls between 100 and 300 micrograms per administration, injected once or twice daily on an empty stomach. Peak growth hormone release occurs 30 to 45 minutes post-injection. Dosing is influenced by bodyweight, goals, and whether ipamorelin is used alone or stacked with a GHRH analog.

Ipamorelin is the first selective growth hormone secretagogue (GHS) to demonstrate GH-releasing potency without meaningfully elevating cortisol or ACTH. That selectivity profile is what separates it from older GHRPs and makes precise dosing both possible and worth getting right. Johansen et al. 1998 established this in the landmark characterisation study: even at doses 200-fold higher than the ED50 for GH release, ipamorelin did not produce ACTH or cortisol elevations significantly different from GHRH alone.

This guide covers dosage ranges, timing, injection technique, reconstitution, the CJC-1295 stack, and the honest picture of what clinical and preclinical evidence supports. If you are searching for a starting framework, read it top to bottom. If you are already running ipamorelin and optimising, use the headers to find what you need.

Affiliate disclosure: This post contains a referral link to Real Peptides. If you purchase through that link, Underground Biohacking earns a small commission at no extra cost to you. We only recommend suppliers whose products we have reviewed for quality documentation.

What Is Ipamorelin and How Does It Work?

Ipamorelin is a synthetic pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It acts as a selective agonist at the ghrelin receptor (GHS-R1a), mimicking the endogenous signal that triggers pituitary somatotrophs to release growth hormone in a pulsatile burst. Johansen et al. 1998

Unlike GHRP-6 and GHRP-2, which stimulate ACTH and cortisol alongside GH, ipamorelin's selectivity means the GH pulse it generates is cleaner. The cortisol and ACTH responses are not eliminated, but they are not amplified beyond the level you would see with endogenous GHRH stimulation. For someone using ipamorelin as part of an anti-ageing or body composition protocol, this matters: chronic cortisol elevation undermines the lean-mass and recovery benefits you are trying to achieve. Sigalos and Pastuszak 2019

GH pulse pharmacokinetics after subcutaneous ipamorelin: peak at approximately 30 to 45 minutes, return to baseline within 2 to 3 hours. Plasma half-life is approximately 2 hours. Raun et al. 1999 documented that 60 to 80 percent of administered dose is recovered from bile and urine as intact peptide, suggesting moderate but not extensive first-pass metabolism via non-subcutaneous routes.

For a deeper look at the receptor pharmacology across the GHS class, see our guide on how growth hormone secretagogues work.

Ipamorelin Dosage Ranges: A Practical Framework

No large-scale, placebo-controlled human dosing trial exists for subcutaneous ipamorelin in anti-ageing or body composition contexts. The only randomised controlled trial in humans used intravenous administration (0.03 mg/kg twice daily) in post-surgical patients. Beck et al. 2014 That trial showed ipamorelin was well tolerated but did not reach statistical significance for its primary endpoint.

Community and compounding-pharmacy protocols for subcutaneous use have converged on the following ranges, informed by the preclinical dose-response data and pharmacokinetic modelling:

Dosage Calculator Reference Table

The table below provides a calculated dosage reference based on bodyweight using the most conservative effective dose (approximately 1.5 mcg/kg) up to the commonly cited ceiling (approximately 3 mcg/kg). This is a research-orientated reference, not a prescription. Always work with a qualified clinician before making changes to your health protocol.

*The 300 mcg ceiling is the conventional upper limit cited in community protocols. Going higher does not appear to produce proportionally greater GH output based on the dose-response plateau documented in preclinical data. Johansen et al. 1998

Starting dose: 100 mcg once daily

This is the entry point most clinicians using compounded ipamorelin recommend. It is sufficient to produce a meaningful GH pulse, low enough that individual tolerance can be assessed, and simple to manage logistically. Run 100 mcg once daily for the first two weeks before considering escalation.

Intermediate dose: 150 to 200 mcg once or twice daily

The most commonly reported range in community protocols and in the compounding pharmacy context. Once-daily dosing pre-sleep captures the overlap with natural nocturnal GH secretion. Twice-daily dosing (morning fasted plus pre-sleep) increases total daily GH stimulus but also increases cost and injection burden. The incremental benefit of twice-daily over once-daily dosing has not been established in human trials.

Higher dose: 200 to 300 mcg per injection

Reserved for users with established tolerance and specific goals around body composition. The preclinical bone growth study in adult female rats showed dose-dependent longitudinal growth rate increases across 18, 90, and 450 mcg/kg SC three times daily for 15 days. Svensson et al. 1999 Extrapolating these animal doses directly to humans is not scientifically appropriate, but the study confirms the dose-response relationship is real and linear within the studied range.

Timing: When to Inject Ipamorelin

Timing ipamorelin injection correctly is arguably more important than the precise dose. Growth hormone secretion is suppressed by insulin and free fatty acids. Inject into a fed state and you blunt the GH pulse before it starts.

Pre-sleep injection: the primary window

The most evidence-informed approach for a once-daily protocol: inject 30 to 60 minutes before sleep, having fasted for at least 90 minutes (ideally 2 hours) after the last meal. This aligns the pharmacologically-induced GH pulse with the natural nocturnal GH surge that occurs in the first hours of slow-wave sleep. Peak GH at 30 to 45 minutes post-injection means the pulse lands as you are falling asleep. Sigalos and Pastuszak 2020

Morning fasted injection: the second window

If running twice daily, the second injection goes upon waking before any food, coffee with milk, or caloric intake. The GH pulse clears within 2 hours, so breakfast at 60 to 90 minutes post-injection is compatible with maintaining the GH response.

Post-training injection: a third option

Some users inject immediately post-training when they train fasted or in a low-insulin state. This is a valid timing window if the training session itself was completed without significant carbohydrate intake. It is not superior to the sleep-window injection for most recovery goals; it is simply a third opportunity to generate a GH pulse during a naturally low-insulin period.

Subcutaneous Injection Technique

For detailed step-by-step guidance on subcutaneous peptide injection technique, our full guide on proper subcutaneous injection technique covers everything from site rotation to syringe selection. The key points specific to ipamorelin:

Syringe and needle selection

Use an insulin syringe (U-100, 0.5 mL or 1 mL barrel). Needle length: 4 mm to 8 mm. Gauge: 29 to 31G. The short fine needle minimises discomfort and reduces the risk of inadvertent intramuscular injection, which changes the pharmacokinetic profile.

Injection sites

Rotate between: lower abdomen (2 to 5 cm from the navel, avoiding the navel itself), outer thigh, and flank. Rotating sites reduces local lipodystrophy from repeated injection and maintains tissue quality at each site. Clean with an alcohol swab and allow to dry before injecting.

Injection method

Pinch a fold of skin between thumb and forefinger. Insert the needle at 45 to 90 degrees depending on the site and your subcutaneous tissue depth. Inject slowly over 5 to 10 seconds. Release the skin fold after withdrawing the needle. Do not rub the site immediately after injection.

Reconstituting Ipamorelin: Step-by-Step

Ipamorelin is supplied as a lyophilised (freeze-dried) powder. It must be reconstituted with bacteriostatic water before use. This is not optional and not interchangeable with sterile water for repeated-use vials.

1. Work at a clean surface. Wipe the vial tops of both the ipamorelin powder vial and the bacteriostatic water vial with separate alcohol swabs. Allow to dry.
2. Draw the required volume of bacteriostatic water into your syringe. For a 10 mg vial, 3 mL of bacteriostatic water gives a concentration of 3.33 mg/mL (3,333 mcg/mL). For a 5 mg vial, 2 mL gives 2.5 mg/mL (2,500 mcg/mL). Adjust to whatever concentration makes your per-dose volume practical.
3. Inject the bacteriostatic water slowly down the inside wall of the ipamorelin vial. Do not spray directly onto the powder cake.
4. Gently swirl until the powder is fully dissolved. Do not shake. Shaking can degrade the peptide.
5. The reconstituted solution should be clear and colourless. Discard if cloudy or particulate matter is visible.
6. Store reconstituted vial at 2 to 8 degrees Celsius (refrigerator). Use within 28 days.

Calculating your draw volume

Once you know your vial concentration, calculate the volume to draw for each dose:

Volume (mL) = Dose (mcg) divided by Concentration (mcg/mL)

Example: 200 mcg dose from a 10 mg vial reconstituted in 3 mL = 200 divided by 3,333 = 0.06 mL (6 units on a U-100 syringe).

Example: 200 mcg dose from a 5 mg vial reconstituted in 2 mL = 200 divided by 2,500 = 0.08 mL (8 units on a U-100 syringe).

Write the concentration and date of reconstitution on the vial label before storing.

The CJC-1295 / Ipamorelin Stack

The most commonly discussed combination in the GH secretagogue literature pairs ipamorelin with CJC-1295 without DAC (also called Modified GRF 1-29). The rationale is mechanistically sound: ipamorelin acts at the ghrelin receptor to trigger GH pulse amplitude, while CJC-1295 without DAC acts at the GHRH receptor to amplify and extend the pulse duration. The two mechanisms are additive rather than redundant. Sigalos and Pastuszak 2019

Practical protocol for the combination:

• Dose ipamorelin at 100 to 200 mcg per injection
• Dose CJC-1295 without DAC at 100 to 200 mcg per injection
• Draw from separate vials into the same syringe if desired (compatibility is generally accepted in community practice, though no formal stability data exists for the combination)
• Inject immediately after drawing; do not pre-mix and store
• Same timing rules apply: fasted state, pre-sleep or morning

For a detailed breakdown of combining these compounds, see combining ipamorelin with GHRH analogs.

Protocol Duration and Cycling

Standard community protocols recommend 8 to 12 weeks of continuous use followed by a 2 to 4 week break. The rationale is receptor sensitivity maintenance and avoidance of potential somatotroph adaptation with prolonged continuous non-physiologic GHS-R stimulation.

A preclinical study of chronic ipamorelin treatment over 21 days showed that rat pituitary somatotroph cells increased their intracellular GH content and secretion granule density, suggesting the tissue adapts dynamically to sustained stimulation. Tolle et al. 2002 Whether this adaptation translates to desensitisation or hyperplasia risk in humans with longer protocols is not established.

The FDA PCAC briefing document (October 2024) flagged concerns about potential somatotroph hyperplasia with chronic non-physiologic GHS-R activation as an unresolved safety question. FDA PCAC 2024 This is not a documented clinical event, but it is a theoretical risk that justifies periodic off-protocol periods and clinician monitoring.

For evidence-based guidance on cycling protocols across the GHS class, see cycling and off-cycle timing.

Side Effects and What to Watch For

Ipamorelin has the cleanest side effect profile among the GHRP class. In the Phase 2 RCT, adverse event incidence was 87.5 percent in the ipamorelin group versus 94.8 percent in placebo, a difference that favoured ipamorelin. Beck et al. 2014 That trial used IV administration in post-surgical patients, so it is not a clean model for subcutaneous use in healthy individuals.

Commonly reported effects in subcutaneous protocols (anecdotal, not formally studied):

• Transient water retention in the first 2 to 3 weeks, typically self-limiting
• Carpal tunnel-like numbness or tingling, particularly with doses above 200 mcg
• Mild injection-site irritation or redness
• Increased appetite, especially at higher doses via ghrelin receptor activity
• Vivid dreams reported by a subset of users
• Mild headache, typically in the first week

The FDA PCAC review (2024) identified concerns about glucose metabolism: chronic ghrelin receptor stimulation can alter insulin sensitivity and glucose homeostasis. FDA PCAC 2024 Anyone with pre-existing glucose dysregulation should have this monitored by a clinician before and during use. Always work with a qualified clinician before making changes to your health protocol.

Regulatory Status and Sourcing

Ipamorelin is not FDA-approved for therapeutic use in humans. It is available through compounding pharmacies under the 503A and 503B frameworks, which allow licensed practitioners to prescribe compounded preparations for specific patients. The FDA PCAC reviewed ipamorelin in October 2024 in the context of whether it is appropriate for compounding, noting the limited human safety database outside the single POI trial. FDA PCAC 2024

It is also available as a research peptide through suppliers who sell to research institutions. Quality documentation matters: look for suppliers providing certificate of analysis (CoA) with HPLC purity data from third-party testing.

If you are sourcing ipamorelin for research purposes, Real Peptides provides independently verified peptides with accessible CoA documentation.

What the Evidence Does and Does Not Support

It is important to be accurate about where the evidence base sits for ipamorelin. The compound has robust preclinical pharmacology data. The GH-releasing mechanism, selectivity profile, and pharmacokinetics are well characterised in animal models and early-phase human studies. Johansen et al. 1998

What is not established in humans:

• Optimal subcutaneous dose for body composition or anti-ageing outcomes
• Long-term safety of chronic subcutaneous administration
• Whether GH pulse amplification translates to meaningful IGF-1 elevation at typical community doses (the preclinical bone study showed no effect on total IGF-1 levels at studied doses) Svensson et al. 1999
• Clinical efficacy for postoperative ileus (the only RCT did not reach significance) Beck et al. 2014

The narrative review by Sigalos and Pastuszak concludes that ipamorelin is a potent selective GH stimulator affecting body composition and adiposity with rare adverse effects, while noting that further human studies are required. Sigalos and Pastuszak 2019

This is the honest position: mechanistically compelling, preclinically validated, human evidence limited but not absent, and community use substantially outpacing the formal evidence base.

Bibliography

1. Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID 9849822
2. Beck DE, Sweeney WB, McCarter MD. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534. PMID 25331030
3. Raun K, Hansen BS, Johansen NL, et al. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Eur J Endocrinol. 1999;140(6):564-571. PMID 9879640
4. Svensson J, Lall S, Dickson SL, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. PMID 10373343
5. Tolle V, Zizzari P, Tomasetto C, et al. Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Growth Horm IGF Res. 2002;12(3):178-185. PMID 12168778
6. Sigalos JT, Pastuszak AW. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Sex Med Rev. 2019;7(1):45-56. PMC7108996
7. Sigalos JT, Pastuszak AW. Growth hormone secretagogues: history, mechanism of action, and clinical development. Reconstr Urol. 2020. doi:10.1002/rco2.9
8. FDA Pharmacy Compounding Advisory Committee Briefing Document: Ipamorelin. October 2024. FDA PCAC 2024

This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.